idea-021 · human · US
For prescription use in outpatient infusion settings, applied and monitored by; oncology nursing staff, to cool and compress the hands and feet of adults receiving weekly; intravenous paclitaxel for breast cancer during each paclitaxel infusion, to reduce the; incidence and severity of chemotherapy-induced peripheral neuropathy of the hands and feet; not for use with oxaliplatin or other agents that cause cold-induced neurotoxicity, and not; for patients with Raynaud phenomenon, cold agglutinin disease, cryoglobulinemia, or; peripheral arterial disease of the limbs to be treated.
Still being built — 5 of 8 wrap criteria met; nothing for you to decide yet. No department has been asked. 0 of 35 claims verified. Nobody has yet written down what it rests on.
A chair-side unit using thermoelectric (Peltier) cooling, with no compressor or refrigerant, circulates chilled coolant through wraps on both hands and both feet, while skin thermistors under each wrap close a control loop on a prescribed skin-temperature target, and a small pneumatic circuit applies low, sequential compression through the same wraps. Applied from before the start of each paclitaxel infusion until after it ends. The intended mechanism is local vasoconstriction and reduced blood flow to the distal limbs during the period of peak drug exposure, limiting delivery of drug to distal nerve endings; the published analogs are frozen gloves and socks (claim 6unverified) and the Paxman cryocompression system (claims 2-3). The design bet against those analogs is tolerability: frozen gloves are uncontrolled and very cold, and the Generator believes intolerance and discontinuation limited at least one randomized trial of them (claim 7unverified). That belief is unverified, and so is the premise that servo control fixes it (claim 32unverified).
In the mechanism, as the candidate file states it — the plain-language paragraph in ## Wrap has not been written yet. Domain: none linked
No business case yet, so nothing here says who writes the cheque. /business-case idea-021 builds one.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-021 replaces this list with the real one.
Why it scored what it did: Claims 1, 2, 10, 14, 21, 22. Scored against the stated intended use (CIPN (chemotherapy-induced peripheral neuropathy) reduction, weekly paclitaxel, breast cancer). Route 1 is Class II (FDA device class II) De Novo (De Novo classification request) with a clean same-logic precedent in DigniCap/878.4360 (claim 10unverified), which is why this is not…the rest of this reasoning
a 2. It is not a 4 because De Novo for a therapeutic claim implies a clinical study against a mixed literature (see Factor 6), claim 1unverified is a null web search rather than a database query, and claim 2unverified says a competitor has been pointed to the same De Novo; if that grant lands first the file drops to route 2 (510(k) (premarket notification) behind Paxman), which is lower burden but forfeits the Breakthrough limb (claim 22unverified, reasoning only). Route 3 (claim 14unverified) is excluded from the score: it abandons the indication.
What would settle it: FDA (US Food and Drug Administration) De Novo and 510(k) databases searched for CIPN / limb cooling / Paxman, plus the DEN150010 (an FDA De Novo decision number) decision summary and eCFR 878.4360 and 890.5720 — all free, an hour of reading.
Why it scored what it did: Claims 11, 12, 13, 15-20. No limb-cooling code identified (claim 12unverified); the console is believed bundled into 96413/96415 (claim 13unverified), so today there is no separate payment at all. The scalp-cooling Category III codes (claim 11unverified) show a code…the rest of this reasoning
can follow, which is why this is 1 rather than 0, but Category III codes carry no guaranteed payment and would take years. Claims 15-20 are a coverage pathway under comment, not in force, and require separate payability this device lacks (claim 16unverified); per the file's own base case they are credited nothing here. Scored with Regulatory at 3, so not a both-below-floor pattern on this draft.
What would settle it: AMA CPT (Current Procedural Terminology) Category III code list and descriptors for 0662T/0663T, plus a CMS (Centers for Medicare & Medicaid Services) HCPCS (Healthcare Common Procedure Coding System) and MPFS/OPPS lookup for any limb-cooling code — free; the FR 2026-16368 text read directly from federalregister.gov.
Why it scored what it did: Claims 23-27. Only one of four components carries a figure: ~310,720 US invasive breast cancer cases (claim 23unverified, ACS modelled estimate). Treated fraction on weekly paclitaxel (24), price (26) and addressable share (27) are explicitly…the rest of this reasoning
unasserted, and the neuropathy prevalence in claim 25unverified is pooled across agents, not paclitaxel-specific. No dollar TAM (total addressable market) can be computed from this file; the 2 is a placeholder at the kill floor reflecting an unpriced, unreimbursed capital-plus-disposables sale into infusion centres, not a size estimate.
What would settle it: SEER/USCS registry counts plus a published US paclitaxel-regimen utilisation study (e.g. SEER-Medicare or NCCN-regimen uptake) for volume, and scalp-cooling list pricing as a price analog — mostly free literature; a licensed…the rest of this gap analysis
oncology-regimen dataset would be a human purchase in the low thousands.
Why it scored what it did: claim 28unverified. Unexamined by the Generator's own disclosure, with Paxman limb cryocompression, thermoelectric therapy garments and skin-temperature-servo cold therapy all expected to be populated art. 2 = not known to be blocked and not…the rest of this reasoning
cleared; explicitly not an FTO (freedom to operate)-blocked kill, since no live patent has been identified.
What would settle it: PatentsView/Google Patents assignee search on Paxman and a keyword search on thermoelectric servo-controlled limb cooling (free), followed by a counsel-run FTO landscape if it survives — several thousand dollars.
Why it scored what it did: Claims 32, 33, 34. The differentiators (Peltier cooling, skin-temperature servo, single-patient wrap sets) are design intent with no prototype (claim 33unverified) and an unproven clinical premise (claim 32unverified); nothing is filed. A first-in-kind De…the rest of this reasoning
Novo would create the classification regulation a follower then 510(k)s against, so even winning route 1 buys time rather than a barrier.
What would settle it: The same patent search as FTO/IP, read for white space on servo-controlled limb cooling — free via Google Patents.
Why it scored what it did: Claims 6, 7, 8, 9, 29, 31, 32, 33. Human signal exists but is weak: the Hanai trial (claim 6unverified) is self-controlled and non-randomized, and the Generator recalls the ACCRU RCT (randomised controlled trial) (claim 7unverified) as showing intolerance and no clear primary-endpoint…the rest of this reasoning
benefit. Claims 8 and 9 are unread. Tolerability and servo benefit (29, 32) are assumptions, and the failure modes in claim 31unverified are uncharacterised. claim 7unverified is the highest-value check in the file: if it reads as recalled, the mechanism rests on one non-randomized study.
What would settle it: The ACCRU RCT (PMC7558814), PMID (PubMed identifier) 33424755 and the 2024 Supportive Care in Cancer meta-analysis read in full from PubMed/PMC — free, a few hours.
Why it scored what it did: Claims 1, 2, 18, 30, 33. No prototype exists (claim 33unverified); route 1 implies a randomized pivotal study in a 12-week chemotherapy course with neuropathy endpoints measured months later, and the base case sells into infusion centres with no…the rest of this reasoning
reimbursement (claims 12, 13, 18) and an unvalidated nursing-workload burden (claim 30unverified). Plausibly the high single-digit to tens of millions of dollars and five-plus years to first dollar; that figure is this Scorer's inference, not a claim in the file.
What would settle it: A cooperative-group or CRO budget quote for a pivotal CIPN trial and an FDA pre-submission meeting to fix the De Novo evidence bar — the pre-sub is free, a CRO quote is a human request.
Why it scored what it did: Claims 2, 3, 4, 5, 34. A named, funded competitor is ahead on the identical mechanism: Paxman in a US SWOG phase III (claim 3unverified) with a stated De Novo route (claim 2unverified) and existing infusion-centre channels via scalp cooling (claim 34unverified);…the rest of this reasoning
further registered cryocompression studies (claims 4, 5) suggest more entrants.
What would settle it: ClinicalTrials.gov records for NCT05642611 (a ClinicalTrials.gov registration number), NCT05095051 and NCT07064798 (status, sponsor, completion dates) plus the FDA De Novo database for any Paxman grant — free.
Why it scored what it did: No claim addresses portfolio fit and no portfolio thesis exists to score against; 3 is a neutral placeholder. Profile read from other factors: a capital-heavy, slow follower-risk bet in oncology supportive care, with no domain dossier…the rest of this reasoning
behind it (claim 35unverified).
What would settle it: A written portfolio thesis from Tier 3 humans — a decision, no direct cost.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-021 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
No claim on this idea has been refuted.
<one sentence, selected from the Scores table's "What would settle it" column>
Nothing is waiting on a decision. The next move above is work, not a choice.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
To finish it:
domains: — run /research**Cheapest next test:** is still the unfilled _template.md placeholder — name the test, or the criterion checks nothingNo human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-021 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-021 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThe packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. <not yet written — later-stage artifact>
What would have to be true.
Cheapest next test: <one sentence, selected from the Scores table's "What would settle it" column>
Where the evidence actually stands. <run python3 engine/scripts/wrap_status.py --candidate idea-021>
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 3 | Claims 1, 2, 10, 14, 21, 22. Scored against the stated intended use (CIPN reduction, weekly paclitaxel, breast cancer). Route 1 is Class II De Novo with a clean same-logic precedent in DigniCap/878.4360 (claim 10unverified), which is why this is not…the rest of this reasoninga 2. It is not a 4 because De Novo for a therapeutic claim implies a clinical study against a mixed literature (see Factor 6), claim 1unverified is a null web search rather than a database query, and claim 2unverified says a competitor has been pointed to the same De Novo; if that grant lands first the file drops to route 2 (510(k) behind Paxman), which is lower burden but forfeits the Breakthrough limb (claim 22unverified, reasoning only). Route 3 (claim 14unverified) is excluded from the score: it abandons the indication. | FDA De Novo and 510(k) databases searched for CIPN / limb cooling / Paxman, plus the DEN150010 decision summary and eCFR 878.4360 and 890.5720 — all free, an hour of reading. |
| Reimbursement pathway | 1 | Claims 11, 12, 13, 15-20. No limb-cooling code identified (claim 12unverified); the console is believed bundled into 96413/96415 (claim 13unverified), so today there is no separate payment at all. The scalp-cooling Category III codes (claim 11unverified) show a code…the rest of this reasoningcan follow, which is why this is 1 rather than 0, but Category III codes carry no guaranteed payment and would take years. Claims 15-20 are a coverage pathway under comment, not in force, and require separate payability this device lacks (claim 16unverified); per the file's own base case they are credited nothing here. Scored with Regulatory at 3, so not a both-below-floor pattern on this draft. | AMA CPT Category III code list and descriptors for 0662T/0663T, plus a CMS HCPCS and MPFS/OPPS lookup for any limb-cooling code — free; the FR 2026-16368 text read directly from federalregister.gov. |
| TAM | 2 | Claims 23-27. Only one of four components carries a figure: ~310,720 US invasive breast cancer cases (claim 23unverified, ACS modelled estimate). Treated fraction on weekly paclitaxel (24), price (26) and addressable share (27) are explicitly…the rest of this reasoningunasserted, and the neuropathy prevalence in claim 25unverified is pooled across agents, not paclitaxel-specific. No dollar TAM can be computed from this file; the 2 is a placeholder at the kill floor reflecting an unpriced, unreimbursed capital-plus-disposables sale into infusion centres, not a size estimate. | SEER/USCS registry counts plus a published US paclitaxel-regimen utilisation study (e.g. SEER-Medicare or NCCN-regimen uptake) for volume, and scalp-cooling list pricing as a price analog — mostly free literature; a licensed…the rest of this gap analysisoncology-regimen dataset would be a human purchase in the low thousands. |
| FTO / IP | 2 | claim 28unverified. Unexamined by the Generator's own disclosure, with Paxman limb cryocompression, thermoelectric therapy garments and skin-temperature-servo cold therapy all expected to be populated art. 2 = not known to be blocked and not…the rest of this reasoningcleared; explicitly not an FTO-blocked kill, since no live patent has been identified. | PatentsView/Google Patents assignee search on Paxman and a keyword search on thermoelectric servo-controlled limb cooling (free), followed by a counsel-run FTO landscape if it survives — several thousand dollars. |
| Moat / defensibility | 1 | Claims 32, 33, 34. The differentiators (Peltier cooling, skin-temperature servo, single-patient wrap sets) are design intent with no prototype (claim 33unverified) and an unproven clinical premise (claim 32unverified); nothing is filed. A first-in-kind De…the rest of this reasoningNovo would create the classification regulation a follower then 510(k)s against, so even winning route 1 buys time rather than a barrier. | The same patent search as FTO/IP, read for white space on servo-controlled limb cooling — free via Google Patents. |
| Mechanism & clinical risk | 2 | Claims 6, 7, 8, 9, 29, 31, 32, 33. Human signal exists but is weak: the Hanai trial (claim 6unverified) is self-controlled and non-randomized, and the Generator recalls the ACCRU RCT (claim 7unverified) as showing intolerance and no clear primary-endpoint…the rest of this reasoningbenefit. Claims 8 and 9 are unread. Tolerability and servo benefit (29, 32) are assumptions, and the failure modes in claim 31unverified are uncharacterised. claim 7unverified is the highest-value check in the file: if it reads as recalled, the mechanism rests on one non-randomized study. | The ACCRU RCT (PMC7558814), PMID 33424755 and the 2024 Supportive Care in Cancer meta-analysis read in full from PubMed/PMC — free, a few hours. |
| Capital intensity & time-to-revenue | 1 | Claims 1, 2, 18, 30, 33. No prototype exists (claim 33unverified); route 1 implies a randomized pivotal study in a 12-week chemotherapy course with neuropathy endpoints measured months later, and the base case sells into infusion centres with no…the rest of this reasoningreimbursement (claims 12, 13, 18) and an unvalidated nursing-workload burden (claim 30unverified). Plausibly the high single-digit to tens of millions of dollars and five-plus years to first dollar; that figure is this Scorer's inference, not a claim in the file. | A cooperative-group or CRO budget quote for a pivotal CIPN trial and an FDA pre-submission meeting to fix the De Novo evidence bar — the pre-sub is free, a CRO quote is a human request. |
| Competitive intensity | 1 | Claims 2, 3, 4, 5, 34. A named, funded competitor is ahead on the identical mechanism: Paxman in a US SWOG phase III (claim 3unverified) with a stated De Novo route (claim 2unverified) and existing infusion-centre channels via scalp cooling (claim 34unverified);…the rest of this reasoningfurther registered cryocompression studies (claims 4, 5) suggest more entrants. | ClinicalTrials.gov records for NCT05642611, NCT05095051 and NCT07064798 (status, sponsor, completion dates) plus the FDA De Novo database for any Paxman grant — free. |
| Strategic fit & portfolio balance | 3 | No claim addresses portfolio fit and no portfolio thesis exists to score against; 3 is a neutral placeholder. Profile read from other factors: a capital-heavy, slow follower-risk bet in oncology supportive care, with no domain dossier…the rest of this reasoningbehind it (claim 35unverified). | A written portfolio thesis from Tier 3 humans — a decision, no direct cost. |
To finish this packet:
domains: — run /research**Cheapest next test:** is still the unfilled _template.md placeholder — name the test, or the criterion checks nothingSource file: knowledge-base/candidates/idea-021.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md